日达仙联合同步放化疗治疗食管癌  

Zadaxin Combined with Concurrent Chemoradiotherapy in the Treatment of Esophageal Carcinoma

作　　者：邬宇飞 李森 

机构地区：[1]张家港澳洋医院三兴分院肿瘤科,江苏张家港215600

出　　处：《肿瘤基础与临床》2013年第4期306-308,共3页journal of basic and clinical oncology

摘　　要：目的观察日达仙联合同步放化疗治疗食管癌的疗效和毒副反应。方法 46例食管癌患者随机分为2组:日达仙组23例采用日达仙联合同步放化疗,日达仙1.6 mg皮下注射,每周2次,放疗采用一前两后三野等中心放疗,化疗采用PF方案;对照组23例采用单纯同步放化疗,方法同日达仙组。结果日达仙组和对照组总有效率分别为91.30%和82.61%,差异无统计学意义(P>0.05);日达仙组放射性食管炎、白细胞减少、血小板减少及恶心呕吐发生率低于对照组,差异有统计学意义(P<0.05)。结论日达仙联合同步放化疗治疗食管癌能减轻放化疗毒副反应。Objective To observe the curative effect and toxicities of zadaxin combined with concurrent chemo- radiotherapy in the treatment of esophageal carcinoma. Methods Forty-six patients with esophageal carcinoma were randomly divided into two groups. Twenty-three patients of the zadaxin group were treated with zadaxin combined with concurrent chemoradiotherapy （ zadaxin 1.6 rag, twice for a week; isocenter radiotherapy ; PF regimen chemotherapy）, 23 patients of the control group were only treated with concurrent chemoradiotherapy. Results The over- all response rate was 91.30% in the zadaxin group, and was 82.61% in the control group, there was no statistical difference in the curative effect between the two groups （ P 〉 0.05 ）. The incidence rates of radiation esophagitis, leucopenia, thrombocytopenia and nausea and vomitting of the zadaxin group were lower than those of the control group （P 〈 0.05 ）. Conclusion Zadaxin combined with concurrent chemoradiotherapy in the treatment of esophageal carcinoma can reduce the toxicities of chemoradiotherapy.

关 键 词：日达仙 食管癌 同步放化疗 

分 类 号：R735.1[医药卫生—肿瘤] R730.58[医药卫生—临床医学]